BACKGROUND: Molecular breast imaging (MBI) depicts functional uptake of targeted radiotracers in the breast using dedicated gamma cameras. METHODS: MBI studies were performed under several institutional protocols evaluating the use of MBI in screening and diagnosis. RESULTS: By using a single-head system, sensitivity for breast cancer detection was 85% (57 of 67) overall and 29% for tumors 5 mm or less in diameter. Sensitivity improved to 91% (117 of 128) overall and 69% for tumors 5 mm or less using a dual-head system. In 650 high-risk patients undergoing breast cancer screening, MBI detected 7 cancers, 5 of which were missed on mammography. In 24 of 149 (16%) breast cancer patients MBI detected additional disease not seen on mammography. The sensitivity of MBI was 88% (83 of 94) for invasive ductal carcinoma, 79% (23 of 29) for invasive lobular carcinoma, and 89% (25 of 28) for ductal carcinoma in situ. CONCLUSIONS: MBI can detect invasive ductal carcinoma, ductal carcinoma in situ, and invasive lobular carcinoma. It has a promising role in evaluating the extent of disease and multifocal disease in the breast for surgical treatment planning.
BACKGROUND: Molecular breast imaging (MBI) depicts functional uptake of targeted radiotracers in the breast using dedicated gamma cameras. METHODS: MBI studies were performed under several institutional protocols evaluating the use of MBI in screening and diagnosis. RESULTS: By using a single-head system, sensitivity for breast cancer detection was 85% (57 of 67) overall and 29% for tumors 5 mm or less in diameter. Sensitivity improved to 91% (117 of 128) overall and 69% for tumors 5 mm or less using a dual-head system. In 650 high-risk patients undergoing breast cancer screening, MBI detected 7 cancers, 5 of which were missed on mammography. In 24 of 149 (16%) breast cancerpatients MBI detected additional disease not seen on mammography. The sensitivity of MBI was 88% (83 of 94) for invasive ductal carcinoma, 79% (23 of 29) for invasive lobular carcinoma, and 89% (25 of 28) for ductal carcinoma in situ. CONCLUSIONS: MBI can detect invasive ductal carcinoma, ductal carcinoma in situ, and invasive lobular carcinoma. It has a promising role in evaluating the extent of disease and multifocal disease in the breast for surgical treatment planning.
Authors: A Ciarmiello; S Del Vecchio; P Silvestro; M I Potena; M V Carriero; R Thomas; G Botti; G D'Aiuto; M Salvatore Journal: J Clin Oncol Date: 1998-05 Impact factor: 44.544
Authors: Bryon Mueller; Michael K O'Connor; Ira Blevis; Deborah J Rhodes; Robin Smith; Douglas A Collins; Stephen W Phillips Journal: J Nucl Med Date: 2003-04 Impact factor: 10.057
Authors: S D Vecchio; A Ciarmiello; M I Potena; M V Carriero; C Mainolfi; G Botti; R Thomas; M Cerra; G D'Aiuto; T Tsuruo; M Salvatore Journal: Eur J Nucl Med Date: 1997-02
Authors: Patricia A Carney; Diana L Miglioretti; Bonnie C Yankaskas; Karla Kerlikowske; Robert Rosenberg; Carolyn M Rutter; Berta M Geller; Linn A Abraham; Steven H Taplin; Mark Dignan; Gary Cutter; Rachel Ballard-Barbash Journal: Ann Intern Med Date: 2003-02-04 Impact factor: 25.391
Authors: Roberta Fusco; Adele Piccirillo; Mario Sansone; Vincenza Granata; Maria Rosaria Rubulotta; Teresa Petrosino; Maria Luisa Barretta; Paolo Vallone; Raimondo Di Giacomo; Emanuela Esposito; Maurizio Di Bonito; Antonella Petrillo Journal: Diagnostics (Basel) Date: 2021-04-30